Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Summit Therapeutics plc announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.
Company inaugurates its new production unit for active pharmaceutical ingredients, the cornerstone of Provepharm’s development
H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc that Amphion has agreed to amend the terms of the Loan Facility with Amphion’s debt provider.
Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.
Tacalyx announced that it has successfully secured €7 million in seed funding.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
Catalyst Pharmaceuticals, Inc., is commenting on trading activity in its common stock and on the current state of its capital resources.